Peroxisome proliferator-activated receptor-gamma and its ligands attenuate biologic functions of human natural killer cells - PubMed (original) (raw)
. 2004 Nov 15;104(10):3276-84.
doi: 10.1182/blood-2004-02-0664. Epub 2004 Jul 20.
Affiliations
- PMID: 15265789
- DOI: 10.1182/blood-2004-02-0664
Free article
Peroxisome proliferator-activated receptor-gamma and its ligands attenuate biologic functions of human natural killer cells
Xia Zhang et al. Blood. 2004.
Free article
Abstract
Interferon-gamma (IFN-gamma) production and cytolytic activity are 2 major biologic functions of natural killer (NK) cells that are important for innate immunity. We demonstrate here that these functions are compromised in human NK cells treated with peroxisome proliferator-activated-gamma (PPAR-gamma) ligands via both PPAR-gamma-dependent and -independent pathways due to variation in PPAR-gamma expression. In PPAR-gamma-null NK cells, 15-deoxy-Delta(12,14) prostaglandin J(2) (15d-PGJ(2)), a natural PPAR-gamma ligand, reduces IFN-gamma production that can be reversed by MG132 and/or chloroquine, and it inhibits cytolytic activity of NK cells through reduction of both conjugate formation and CD69 expression. In PPARgamma-positive NK cells, PPAR-gamma activation by 15d-PGJ(2) and ciglitazone (a synthetic ligand) leads to reduction in both mRNA and protein levels of IFN-gamma. Overexpression of PPAR-gamma in PPAR-gamma-null NK cells reduces IFN-gamma gene expression. However, PPAR-gamma expression and activation has no effect on NK cell cytolytic activity. In addition, 15d-PGJ(2) but not ciglitazone reduces expression of CD69 in human NK cells, whereas CD44 expression is not affected. These results reveal novel pathways regulating NK cell biologic functions and provide a basis for the design of therapeutic agents that can regulate the function of NK cells within the innate immune response.
Similar articles
- Upregulation of MIP-2 (CXCL2) expression by 15-deoxy-Delta(12,14)-prostaglandin J(2) in mouse peritoneal macrophages.
Kim HY, Kim HS. Kim HY, et al. Immunol Cell Biol. 2007 Jan;85(1):60-7. doi: 10.1038/sj.icb.7100001. Epub 2006 Nov 28. Immunol Cell Biol. 2007. PMID: 17130903 - Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone, in reperfusion injury: role of nuclear factor-kappaB, heat shock factor 1, and Akt.
Zingarelli B, Hake PW, Mangeshkar P, O'Connor M, Burroughs TJ, Piraino G, Denenberg A, Wong HR. Zingarelli B, et al. Shock. 2007 Nov;28(5):554-63. doi: 10.1097/shk.0b013e31804f56b9. Shock. 2007. PMID: 17589386 - The role of 15-deoxy-delta(12,14)-prostaglandin J(2), an endogenous ligand of peroxisome proliferator-activated receptor gamma, in tumor angiogenesis.
Kim EH, Surh YJ. Kim EH, et al. Biochem Pharmacol. 2008 Dec 1;76(11):1544-53. doi: 10.1016/j.bcp.2008.07.043. Epub 2008 Aug 14. Biochem Pharmacol. 2008. PMID: 18771658 Review. - Hormone regulation of microglial cell activation: relevance to multiple sclerosis.
Drew PD, Storer PD, Xu J, Chavis JA. Drew PD, et al. Brain Res Brain Res Rev. 2005 Apr;48(2):322-7. doi: 10.1016/j.brainresrev.2004.12.020. Epub 2005 Jan 19. Brain Res Brain Res Rev. 2005. PMID: 15850670 Free PMC article. Review.
Cited by
- Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.
Wang C, Shi Y, Wang X, Ma H, Liu Q, Gao Y, Niu J. Wang C, et al. Front Immunol. 2022 Jul 8;13:940688. doi: 10.3389/fimmu.2022.940688. eCollection 2022. Front Immunol. 2022. PMID: 35880178 Free PMC article. Review. - Efficacy of intralipid administration to improve in vitro fertilization outcomes: A systematic review and meta-analysis.
Han EJ, Lee HN, Kim MK, Lyu SW, Lee WS. Han EJ, et al. Clin Exp Reprod Med. 2021 Sep;48(3):203-210. doi: 10.5653/cerm.2020.04266. Epub 2021 Aug 26. Clin Exp Reprod Med. 2021. PMID: 34488285 Free PMC article. - PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells.
Gutting T, Hauber V, Pahl J, Klapproth K, Wu W, Dobrota I, Herweck F, Reichling J, Helm L, Schroeder T, Li B, Weidner P, Zhan T, Eckardt M, Betge J, Belle S, Sticht C, Gaiser T, Boutros M, Ebert MPA, Cerwenka A, Burgermeister E. Gutting T, et al. Oncoimmunology. 2021 May 5;10(1):1906500. doi: 10.1080/2162402X.2021.1906500. Oncoimmunology. 2021. PMID: 34026331 Free PMC article. - Minireview: Challenges and opportunities in development of PPAR agonists.
Wright MB, Bortolini M, Tadayyon M, Bopst M. Wright MB, et al. Mol Endocrinol. 2014 Nov;28(11):1756-68. doi: 10.1210/me.2013-1427. Epub 2014 Aug 22. Mol Endocrinol. 2014. PMID: 25148456 Free PMC article. Review. - The Role of PPARs in Placental Immunology: A Systematic Review of the Literature.
Hutter S, Knabl J, Andergassen U, Jeschke U. Hutter S, et al. PPAR Res. 2013;2013:970276. doi: 10.1155/2013/970276. Epub 2013 Mar 10. PPAR Res. 2013. PMID: 23554810 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous